Structure-based development of potent and selective type-II kinase inhibitors of RIPK1.
Qin Y, Li D, Qi C, Xiang H, Meng H, Liu J, Zhou S, Gong X, Li Y, Xu G, Zu R, Xie H, Xu Y, Xu G, Zhang Z, Chen S, Pan L, Li Y, Tan L.
Qin Y, et al. Among authors: liu j.
Acta Pharm Sin B. 2024 Jan;14(1):319-334. doi: 10.1016/j.apsb.2023.10.021. Epub 2023 Nov 8.
Acta Pharm Sin B. 2024.
PMID: 38261830
Free PMC article.